Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer... Show more
KURA is expected to report earnings to rise 6.90% to -82 cents per share on October 29
Q3'26
Est.
$-0.82
Q2'26
Beat
by $0.11
Q1'26
Est.
$-0.83
Q4'25
Missed
by $0.66
Q3'25
Missed
by $0.10
The last earnings report on August 12 showed earnings per share of -76 cents, beating the estimate of -87 cents. With 799.79K shares outstanding, the current market capitalization sits at 1.18B.